Oncology & Cancer

FDA: Cyramza approval now includes non-small-cell lung CA

(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.

Oncology & Cancer

New at-risk group identified for gastrointestinal stromal tumors

Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach ...

Oncology & Cancer

Botox for stomach cancer? No, but the research is fascinating

Amid continuing tales of global woe, Thursday morning's news carried one of those quirky 'fancy-that!' medical research stories that often captures the imagination, but which can inadvertently raise false hope in patients.

Oncology & Cancer

New view of stomach cancer could hasten better therapies

In a massive effort to catalog the molecular causes of stomach cancer, scientists, including researchers at Dana-Farber Cancer Institute, have identified four subtypes of tumors based on shared mutations and other molecular ...

page 14 from 23